Announced
Completed
Financials
Tags
ocular diseases
Private
Completed
Joint Venture
Biotechnology
Japan
United States
Majority
Cross Border
Friendly
Single Bidder
Synopsis
Otsuka Pharmaceutical, a healthcare company with a corporate philosophy, and ShapeTX, a programmable medicine company using AI and RNA to end genetic diseases, formed a joint venturet to develop intravitreally-delivered adeno-associated viruses for ocular diseases. Financial terms were not disclosed. “We’ve built our AAVid platform on generative AI approaches akin to those behind Midjourney and DALL-E 2 to tackle industry challenges with gene therapy delivery. By incorporating diffusion models, our platform is designing novel medicines that transcend the boundaries of what is possible experimentally. Our collaboration with Otsuka marks an exciting chapter in our journey as we extend the reach and impact of our technologies to help as many patients as possible,” Francois Vigneault, ShapeTX Co-Founder and CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.